{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-012249","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.958031+00:00","generated_at":"2026-05-27T11:29:37.178584+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lyell Immunopharma receives Nasdaq delisting notice for bid price below $1.00","bullets":["Notice received Jan 23, 2025: common stock bid price below $1.00 for 33 consecutive business days.","Company has 180 calendar days, until July 22, 2025, to regain compliance by closing at $1.00 for 10 consecutive days.","If not compliant by July 22, may qualify for an additional 180-day period by transferring to Nasdaq Capital Market.","Company will evaluate options, including a reverse stock split, to cure the deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-012249","json":"https://secwatch.observer/filing/0001193125-25-012249.json","markdown":"https://secwatch.observer/filing/0001193125-25-012249.md","text":"https://secwatch.observer/filing/0001193125-25-012249.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/d884359d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T11:29:37.178584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1383847858e313a1029bbbd3833b65109d3c7cb0","claim":"Lyell Immunopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001493152-26-026529","ticker":"HCWB","company_name":"HCW Biologics Inc.","filed_at":"2026-06-01T11:30:18+00:00","headline":"Nasdaq panel grants HCW Biologics extension to July 29, 2026 to regain $1 bid price compliance","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026529","json":"https://secwatch.observer/filing/0001493152-26-026529.json","markdown":"https://secwatch.observer/filing/0001493152-26-026529.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226026529/0001493152-26-026529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226026529/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm","comparable_excerpt":"ng the exception period that may\naffect the Company’s compliance with Nasdaq requirements. If the Company regains compliance and satisfies the terms of the exception,\nthe Panel intends to impose a Discretionary Panel Monitor on the Company for an additional one-year period, pursuant to Listing Rule\n5815(d)(4)(A). SIGNATURES Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized. HCW BIOLOGICS INC. Date: June 1, 2026 By: /s/\n Hing C. Wong Hing C. Wong, Founder and Chie","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226026529/0001493152-26-026529-index.htm"}},{"accession":"0001213900-26-060662","ticker":"TNON","company_name":"Tenon Medical, Inc.","filed_at":"2026-05-22T21:15:15+00:00","headline":"Tenon Medical receives Nasdaq delisting notice for failing minimum stockholders' equity","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060662","json":"https://secwatch.observer/filing/0001213900-26-060662.json","markdown":"https://secwatch.observer/filing/0001213900-26-060662.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/ea0291962-8k_tenon.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm","comparable_excerpt":"May 21, 2026, Tenon Medical, Inc. (the “Company”)\nreceived a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 21, 2026, notifying\nthe Company that it is no longer in compliance with the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1560293/000121390026060662/0001213900-26-060662-index.htm"}},{"accession":"0001213900-26-060267","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-05-22T01:40:52+00:00","headline":"AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060267","json":"https://secwatch.observer/filing/0001213900-26-060267.json","markdown":"https://secwatch.observer/filing/0001213900-26-060267.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/ea0291955-8k_allinfuture.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm","comparable_excerpt":"May 19, 2026, All In FutureTech Alliance,\nInc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)\nfrom the Listing Qualifications Department (the “Staff”) of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm"}},{"accession":"0001213900-26-058167","ticker":"SNYR","company_name":"Synergy CHC Corp.","filed_at":"2026-05-18T13:01:37+00:00","headline":"Synergy CHC receives Nasdaq delisting notice for bid price below $1.00","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-058167","json":"https://secwatch.observer/filing/0001213900-26-058167.json","markdown":"https://secwatch.observer/filing/0001213900-26-058167.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/0001213900-26-058167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/ea0291276-8k_synergy.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm","comparable_excerpt":"May 15, 2026, Synergy CHC Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of\nThe Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the closing","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1562733/000121390026058167/0001213900-26-058167-index.htm"}},{"accession":"0001213900-26-055912","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-05-13T21:00:25+00:00","headline":"iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance","event_type":"other_material","sec_items":["1.01","3.01","3.02","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055912","json":"https://secwatch.observer/filing/0001213900-26-055912.json","markdown":"https://secwatch.observer/filing/0001213900-26-055912.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/ea0290143-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm","comparable_excerpt":"minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum\nBid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026055912/0001213900-26-055912-index.htm"}},{"accession":"0001829126-26-004960","ticker":"PMI","company_name":"Picard Medical, Inc.","filed_at":"2026-05-11T21:08:14+00:00","headline":"Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity","event_type":"other_material","sec_items":["1.01","3.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004960","json":"https://secwatch.observer/filing/0001829126-26-004960.json","markdown":"https://secwatch.observer/filing/0001829126-26-004960.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/0001829126-26-004960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/picardmedical_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm","comparable_excerpt":"May 8, 2026, the Company received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reported a stockholders’ equity of approximately $3.8 million as of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/0001829126-26-004960-index.htm"}},{"accession":"0001104659-26-057974","ticker":"HUMA","company_name":"Humacyte, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Humacyte receives Nasdaq deficiency notice for bid price below $1.00; 180 days to comply","event_type":"other_material","sec_items":["3.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057974","json":"https://secwatch.observer/filing/0001104659-26-057974.json","markdown":"https://secwatch.observer/filing/0001104659-26-057974.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/0001104659-26-057974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/tm2614071d1_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm","comparable_excerpt":"May 4, 2026, Humacyte, Inc. (the “Company”)\nreceived a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification\nthat, for the 30 consecutive business days ended May 1, 2026, th","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926057974/0001104659-26-057974-index.htm"}},{"accession":"0001749723-26-000045","ticker":"NFE","company_name":"New Fortress Energy Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"New Fortress Energy receives Nasdaq delisting notice for bid price below $1.00","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001749723-26-000045","json":"https://secwatch.observer/filing/0001749723-26-000045.json","markdown":"https://secwatch.observer/filing/0001749723-26-000045.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1749723/000174972326000045/0001749723-26-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1749723/000174972326000045/nfe-20260501.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consec","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525012249/0001193125-25-012249-index.htm","comparable_excerpt":"May 1, 2026, New Fortress Energy Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closi","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1749723/000174972326000045/0001749723-26-000045-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}